Walden Biosciences Reveals Favorable Preliminary Results from Phase 1+ Trial of WAL0921 for Kidney Disease Therapy

April 15, 2024 —Walden Biosciences, a private clinical development company, has reported positive results from its Phase 1+ study of WAL0921, a humanized monoclonal antibody designed to bind and inhibit the pathological activity of soluble urokinase plasminogen activator receptor (suPAR), which is linked to kidney diseases. The study, which involved 40 healthy subjects, showed that WAL0921 was safe and effective in rapidly reducing circulating free suPAR levels in a dose-dependent manner. This finding suggests that WAL0921 could offer a new therapeutic approach for various kidney conditions. 

The Phase 1+ clinical trial was a single-center, placebo-controlled study that assessed the safety, pharmacokinetics, and pharmacodynamics of WAL0921. Andrew Blair, M.D., Walden's Chief Medical Officer, highlighted the significance of the study's findings, stating that WAL0921's ability to target suPAR directly could represent a novel treatment strategy for kidney diseases. 

Walden Biosciences plans to move forward with a Phase 2 Basket study for glomerular kidney diseases in the second quarter of 2024, based on the promising results. The company specializes in developing transformative therapies for kidney diseases, focusing on treatments that prevent damage, slow disease progression, and restore kidney function. Walden's pipeline includes a monoclonal antibody that targets suPAR, a small molecule aimed at restoring dynamin function, and a novel anti-fibrotic biologic in preclinical research. These programs aim to provide breakthrough, disease-modifying therapies that can be combined with standard care to improve kidney disease treatment outcomes. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!